More Stories

Informist, Wednesday, Aug. 5, 2026

 

Please click here to read all liners published on this story

--Aurobindo Pharma Apr-Jun consol net profit INR 10.33 bln 
--Analysts saw Aurobindo Pharma Apr-Jun consol net profit at INR 9.78 bln 
--Aurobindo Pharma Apr-Jun consol revenue INR 91.50 bln 
--Analysts saw Aurobindo Pharma Apr-Jun consol revenue at INR 89.25 bln 
--Aurobindo Pharma Apr-Jun consol PAT INR 10.33 bln vs INR 8.25 bln yr ago 
--Aurobindo Pharma Q1 consol sales INR 91.50 bln vs INR 78.68 bln yr ago 
--Aurobindo Pharma Q1 consol operating EBITDA INR 19.24 bln vs INR 16.03 bln 
--Aurobindo Pharma Q1 consol operating EBITDA margin 21.0% vs 20.4% year ago 
--Aurobindo Pharma Q1 US formulations sales INR 37.70 bln vs INR 34.88 bln 
--Aurobindo Pharma Q1 Europe formulation sales INR 29.4 bln vs INR 23.4 bln 
--Aurobindo Pharma Q1 anti-retroviral sales INR 3.30 bln vs INR 3.55 bln 
--Aurobindo Pharma Q1 API revenue INR 10.49 bln vs INR 9.16 bln yr ago 
--Aurobindo Pharma net cash at INR 3.97 bln on Jun 30 vs INR 30.02 bln Mar 31 

 

By Gunjan Rajput 

 

NEW DELHI – Aurobindo Pharma Ltd. Wednesday reported higher year-on-year consolidated net profit for the June quarter, beating analysts' consensus estimate, as revenues rose on strong performance across geographic segments. The revenue growth was driven by volume gains and new product launches in the US base business, while higher other income also supported the bottom line. This marks the fourth consecutive quarter of on-year net profit growth, the strongest pace in the period, and the 15th straight quarter of on-year revenue growth.

 

The pharmaceutical company's Apr-Jun consolidated net profit rose over 25% to INR 10.33 billion from INR 8.25 billion a year ago. Analysts had estimated the net profit at INR 9.78 billion. Revenue from operations increased over 16% to INR 91.50 billion, compared with INR 78.68 billion a year earlier, surpassing the Street's expectation of INR 89.25 billion. Aurobindo Pharma's other income rose 151% on year to INR 2.64 billion and total income rose 18% to INR 94.15 billion for the reporting quarter.

 

The company's total expenses rose 16% on year to INR 78.58 billion. Input costs, which made up 37% of total expenses, grew over 14% to INR 28.94 billion. Other expenses increased 20% on year to INR 21.62 billion. Expenses related to employee benefits also rose 20% to INR 14.80 billion and expenses tied to purchases of stock-in-trade grew 15% on year to INR 9.32 billion.

 

The company's consolidated operating earnings before interest, tax, depreciation, and amortisation rose to INR 19.24 billion from INR 16.03 billion a year ago. The operating EBITDA margin expanded to 21% from 20.4% a year earlier.

 

The US formulations business, Aurobindo Pharma's largest segment, accounted for 41.2% of consolidated revenues for the June quarter. Revenues from this business rose over 8% on year to INR 37.70 billion, driven by volume gains and new product launches. Excluding generic Revlimid, US revenues rose 5% sequentially. During the quarter, the company launched 10 products in the US market and received final approvals for 10 products, according to the investor presentation. 

 

Revenues from the Europe business rose 26% on year to INR 29.37 billion while revenues from growth markets increased 38% to INR 10.63 billion. The company's revenue from the active pharmaceutical ingredients business rose 15% to INR 10.49 billion. However, anti-retroviral sales declined 7% to INR 3.30 billion.

 

Aurobindo Pharma reported a net cash position of INR 3.97 billion as on Jun. 30, compared with INR 30.02 billion at the end of March. The company also generated free cash flow of $98 million during the June quarter and reported a net cash position, including investments, of about $42 million as of Jun. 30. This was after spending $247 million on the Lannett acquisition and $85 million on buying back shares. The net capital expenditure during the quarter stood at $78 million, primarily towards capability enhancements and new business development, according to the investor presentation.